Targeted cellular immunotherapy for T cell malignancies

In a recent study, Maciocia et al. develop a novel T cell receptor beta (TCRB) constant C1-chain-directed cellular immunotherapy for the treatment of T cell malignancies.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Figure 1: Principles of anti-TCRB-C1 CAR T cell therapy.


  1. 1

    Pishko, A. & Nasta, S.D. Transl. Cancer Res. 6, 93–103 (2017).

  2. 2

    Ramos, C.A. et al. J. Clin. Invest. 126, 2588–2596 (2016).

  3. 3

    Toyonaga, B., Yoshikai, Y., Vadasz, V., Chin, B. & Mak, T.W. Proc. Natl. Acad. Sci. USA 82, 8624–8628 (1985).

  4. 4

    Schwartz, R.H. Annu. Rev. Immunol. 3, 237–261 (1985).

  5. 5

    Warner, K. et al. Curr. Hematol. Malig. Rep. 8, 163–172 (2013).

  6. 6

    Nikolich-Zugich, J., Slifka, M.K. & Messaoudi, I. Nat. Rev. Immunol. 4, 123–132 (2004).

Download references

Author information

Correspondence to Adolfo Ferrando.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Palomero, T., Ferrando, A. Targeted cellular immunotherapy for T cell malignancies. Nat Med 23, 1402–1403 (2017).

Download citation

Further reading